EUVIMEDObjevte EUVIMED
Crossref

Cryo-Crystallization of Inhalable Budesonide Ultrafine Crystals with Enhanced Aerosol Performance: Mechanism and Evaluation

Shengzheng Guo, Ziyi Liu, Yuxin Zhang, Jingkang Wang, Zhenguo Gao iD, Junbo Gong iD

ACS Applied Materials & Interfaces · 2025

DOI: 10.1021/acsami.5c05902 ↗

At a glance

Journal article in ACS Applied Materials & Interfaces, 2025. Written by Shengzheng Guo and 5 co-authors. Institution: School of Chemical Engineering and Technology, State Key Laboratory of Chemical Engineering, Tianjin University, Tianjin 300072, People's Republic of…. Major MEDLINE topics: Budesonide. 61 references. Funded by: National Natural Science Foundation of China, Key Technology Research and Development Program of Shandong Province.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Dry powder inhalation (DPI) therapy offers effective treatment for pulmonary diseases, providing high drug delivery efficiency, minimal side effects, and enhanced patient compliance. The DPI efficacy depends critically on drug particle physicochemical properties and drug-carrier interactions, while the quantitative mechanisms and optimization policy are still unclear. Here, we introduce a microdroplet cryo-crystallization (MCC) strategy, producing superior powder properties in terms of particle size, shape, and crystallinity compared with traditional milling and spray drying techniques. The aerosol evaluation indicated that an obvious improvement in the fine particle fraction (FPF) to 58-62% depends on the variation of the air blowing speed, which is the highest value compared to the commercialized formulation. The subsequent formulation mechanism studies revealed improved powder flowability (basic flowability energy of 124 mJ vs 146 mJ for the conventional type). An AFM test demonstrated the cohesion of BUDmc (Fc = 70.50 nN) was lower than that of BUDca (Fc = 93.20 nN), giving DPImc a more desirable CAB than DPIca (1.02 vs 1.07 for BUDca), which ensures the mixing homogeneity of DPImc and facilitates the effective detachment of drug particles. These results suggest that MCC is a promising technique for producing inhalable budesonide (BUD) with superior physicochemical properties and aerosolization performance, and the quantitative mechanism study gives theoretical guidance for the further development of the DPI formulation.

Subjects

MeSH terms (MEDLINE)

BudesonideAerosolsCrystallizationParticle SizeAdministration, InhalationDry Powder InhalersPowders

Author keywords

aerosol performancebudesonidecohesive−adhesive balancecryo-crystallizationdry powder inhalation

Substances

BudesonideAerosolsPowders

Authors and institutions

  • School of Chemical Engineering and Technology, State Key Laboratory of Chemical Engineering, Tianjin University, Tianjin 300072, People's Republic of China.

ORCID profiles: Zhenguo Gao, Junbo Gong

Funding

  • National Natural Science Foundation of China
  • Key Technology Research and Development Program of Shandong Province

Cite

APA

Guo, S., Liu, Z., Zhang, Y., Wang, J., Gao, Z., & Gong, J. (2025). Cryo-Crystallization of Inhalable Budesonide Ultrafine Crystals with Enhanced Aerosol Performance: Mechanism and Evaluation. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c05902

Vancouver

Guo S, Liu Z, Zhang Y, Wang J, Gao Z, Gong J. Cryo-Crystallization of Inhalable Budesonide Ultrafine Crystals with Enhanced Aerosol Performance: Mechanism and Evaluation. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.5c05902

BibTeX
@article{Guo2025,
  author = {Guo, Shengzheng and Liu, Ziyi and Zhang, Yuxin and Wang, Jingkang and Gao, Zhenguo and Gong, Junbo},
  title = {Cryo-Crystallization of Inhalable Budesonide Ultrafine Crystals with Enhanced Aerosol Performance: Mechanism and Evaluation},
  journal = {ACS Applied Materials & Interfaces},
  year = {2025},
  doi = {10.1021/acsami.5c05902}
}
Start for free →